VBI Vaccines Inc
OTC:VBIVQ

Watchlist Manager
VBI Vaccines Inc Logo
VBI Vaccines Inc
OTC:VBIVQ
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: 14.3k USD

VBI Vaccines Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

VBI Vaccines Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
VBI Vaccines Inc
NASDAQ:VBIV
EPS (Diluted)
-$3
CAGR 3-Years
20%
CAGR 5-Years
30%
CAGR 10-Years
19%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

VBI Vaccines Inc
Glance View

Market Cap
14.3k USD
Industry
Biotechnology

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2001-11-19. The firm develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers including glioblastoma (GBM). Its PreHevbrio (Hepatitis B Vaccine [Recombinant]), which contains S, pre-S2, and pre-S1 HBV surface antigens and is an approved 3-antigen HBV vaccine for adults. Its Prophylactic candidates include VBI-2900, which is a coronavirus vaccine Program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901, which targets CMV proteins present in tumor cells. The firm is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901.

VBIVQ Intrinsic Value
Not Available

See Also

What is VBI Vaccines Inc's EPS (Diluted)?
EPS (Diluted)
-3.4 USD

Based on the financial report for Mar 31, 2024, VBI Vaccines Inc's EPS (Diluted) amounts to -3.4 USD.

What is VBI Vaccines Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
19%

Over the last year, the EPS (Diluted) growth was 76%. The average annual EPS (Diluted) growth rates for VBI Vaccines Inc have been 20% over the past three years , 30% over the past five years , and 19% over the past ten years .

Back to Top